D6-B483
/ Ashvattha Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 11, 2021
Ashvattha Therapeutics to Present at 2021 Sachs 7th Annual Digital Immuno-Oncology Innovation Forum
(Businesswire)
- “Ashvattha Therapeutics…announced that it will present at the Sachs 7th Annual Immuno-Oncology Innovation Forum, held virtually, May 18-20, 2021…Ashvattha is currently on track to initiate a D6-B483 Phase 1 study in patients with glioblastoma multiforme or brain metastases by end of 2021.”
New P1 trial • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology
1 to 1
Of
1
Go to page
1